Thursday, May 8, 2025

Enhanced CAR T cell therapy offers new strategy for lymphoma

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

from Latest Science News -- ScienceDaily https://ift.tt/pto7C5h
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Ozempic may have revealed the brain’s hidden “craving center”

Ozempic-like drugs appear to weaken more than hunger—they may also reduce cravings for alcohol and other addictive substances. Scientists ar...